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Background: Using the recommended one-stent strategy for bifurcation treatment,
a strategy of routine ﬁnal kissing balloon dilatation (FKBD) have resulted in longer
and more complex procedures and mixed midterm clinical results as compared to
a strategy of provisional FKBD. Delayed strut coverage, ﬂow limiting neointimal
growth on stent struts jailing the side branch ostium, but also stent distortion after
FKBD, might affect long term clinical results. Here we present the 3-year clinical
follow-up in the Nordic-Baltic Bifurcation Study III (NCT00914199) on routine vs.
provisional FKBD.
Methods:We randomized 477 patients with a bifurcation lesion to FKBD (n¼238) or
no-FKBD (n¼239) after main vessel stenting. The 6-month primary end-point was
a composite of major adverse cardiac events (MACE); cardiac death, non-procedure
related index lesion myocardial infarction, target lesion revascularization or stent
thrombosis.
Results: No patients were lost to follow-up. The 36-month MACE rates were 9.7% vs.
10.0% (p¼0.89) in the FKBD and no-FKBD groups, respectively. Total death was
5.9% vs. 2.1% (p¼0.03), cardiac death was 2.1% vs. 0.4% (p¼0.10), target lesion
revascularization was 6.3% vs. 8.3% (p¼0.39), and deﬁnite stent thrombosis was
found in 0.8% vs. 1.3% (p¼0.66) in the FKBD and no-FKBD groups, respectively. In
the subgroup of true bifurcation lesions 36-month MACE rates were 9.1% in the
FKBD group vs. 12.7% (p¼0.37) in the no-FKBD group.
Conclusions: A strategy of routine FKBD compared to provisional FKBD in main
vessel-only stenting did not improve 36-month clinical outcome after stenting of the
main vessel in coronary bifurcation lesions.
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Background: Despite many studies concerning percutaneous coronary intervention
(PCI) in patients with unprotected left main disease (ULM), there are a little data
available regarding clinical outcomes between following 1st and 2nd generation drug
eluting stent (DES) implantation.
Methods: Between January 2005 and December 2011, 1029 consecutive patients who
were treated for ULM lesion with DES (1st DES; 765 patients and 2nd DES; 264
patients) were enrolled in this study. The study end point was major adverse cardiac
events (MACE) deﬁned as a composite of cardiac death, nonfatal myocardial
infarction (MI) and target lesion revascularization (TLR). Furthermore, TLR for mainB10 JACC Vol 62/18/Suppl B j October 27–Novembbranch (TLR-MB) including ULM itself and proximal Left anterior descending artery
and TLR for side branch (TLR-SB) including at ostial left circumﬂex artery alone
were evaluated.
Results: Baseline clinical and angiographic characteristics were similar between the
two groups. At 1-year, MACE were not different between the 2 groups (16.81.4% in
the 1st DES vs. 12.22.0% in the 2nd DES, HR, 0.924; 95%CI, 0.686–1.244,
p¼0.601). The occurrence of TLR-MB was similar (6.0%0.9 vs. 4.7%1.3%,
respectively, HR, 0.785; 95%CI 0.446–1.381, p¼0.401). However, 2nd DES were
associated with a lower occurrence of TLR-SB as compared to 1st DES (10.41.1%
versus 6.31.5%, respectively; adjusted HR 0.601; 95% CI, 0.411–1.034, p¼0.069).
Conclusions: This study suggests that there were not statistically signiﬁcant
improvements between1st or 2nd DES, concerning mortality and TLR-MB in patients
undergoing PCI for ULM disease. However, usage of 2nd DES may contribute to
reduce of TLR-SB.
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Background: Limited data exists about the incidence, management and outcomes
following presentation with emergency left mainstem coronary artery occlusion
(LMSO).
Methods: We searched the national British Cardiovascular Intervention Society
database of all Primary PCI cases in the UK from January 2007 to December 2011.
Patients' vital status was obtained through linkage with the national death register.
Results: During the observation period, 1139 patients presenting with ST elevation
underwent PPCI to unprotected LMS (1.5% of PPCIs). Information on TIMI ﬂow and
severity of stenosis was available in 785 (mean age 69 years). 328/785 patients pre-
sented with LMSO (TIMI ﬂow 0/1 and stenosis >75%) and were more likely to be
male (75% vs 67%, p¼0.02) and less likely to have a history of MI (16% vs 22%,
p¼0.03). LMSO presentation was associated with a doubling in risk of peri-procedural
cardiogenic shock (58% vs 29%, p<0.001) and a larger proportion of patients required
inotropic or mechanical circulatory support (p<0.001). 40% of patients with LMSO
died during the hospital admission compared with 19% of those who did not present
with occlusion (p<0.001). This difference in outcomes was only partly explained by
the higher shock rate (see Figure). There was no evidence to suggest that death rates
continued to diverge in those with or without LMSO beyond 30 days of follow-up
(43% vs 21% and 55% vs 32% for 30-day and 1-year mortality, respectively).Conclusions: In this largest cohort of patients presenting with LMSO and undergoing
PPCI, acute outcomes are predictably poor but long-term outcomes for survivors are
encouraging.
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Background: The aim of this prospective, international, ﬁrst-in-man study is to assess
effectiveness and safety of dedicated bifurcation sirolimus-eluting stent BiOSS LIM
(Balton, Poland) in patients with stable coronary artery disease (CAD) and NSTE-ACS.
Methods: Between October 2011 and October 2012 patients with CAD or NSTE-
ACS who signed informed consent were included into the study. The enrollment waser 1, 2013 j TCT Abstracts/ORAL/Bifurcation and Left Main Stenting
